Media Articles Related to Kaletra (Lopinavir / Ritonavir)
FDA approves diagnostic test to differentiate between types of HIV infection
Source: HIV / AIDS News From Medical News Today [2015.07.24]
The U.S. Food and Drug Administration has approved the Bio-Rad BioPlex 2200 HIV Ag-Ab assay, the first FDA-approved diagnostic that differentiates between HIV-1 antibodies, HIV-2 antibodies, and...
Study finds PrEP use feasible among high-risk groups in US community settings
Source: HIV / AIDS News From Medical News Today [2015.07.22]
A majority of men who have sex with men (MSM) and transgender women (TGW) at high risk for HIV infection took anti-HIV medication for pre-exposure prophylaxis (PrEP), most of the time, in a...
PrEP Roll-out in Botswana Proves Worthy (CME/CE)
Source: MedPage Today OB/Gyn [2015.07.22]
(MedPage Today) -- No HIV infections in initial year-long program.
HPTN 052 demonstrates sustained benefit of early antiretroviral therapy
Source: HIV / AIDS News From Medical News Today [2015.07.21]
Antiretroviral therapy (ART) for HIV infection provides lasting protection against the sexual transmission of the virus from infected men and women to their HIV-uninfected sexual partners...
Host genetics played a role in vaccine efficacy in the RV144 HIV vaccine trial
Source: HIV / AIDS News From Medical News Today [2015.07.16]
New findings published July 15 in the journal Science Translational Medicine show that host genetics played a role in protection against HIV infection in the landmark RV144 vaccine trial conducted in...
Published Studies Related to Kaletra (Lopinavir / Ritonavir)
Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers. [2011.07]
The objective of this investigation was to evaluate the pharmacokinetic interaction of lopinavir/ritonavir (LPV/r) with BILR 355. In group A, 26 healthy participants were administered LPV/r (400mg/100mg) twice daily for 14 days, followed by coadministration of BILR 355, 150 mg twice daily for an additional 7 days...
Beneficial effects of a switch to a Lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression. [2011.06]
The purpose of this study was to determine if switching to an Lopinavir/ritonavir (LPV/r)-containing regimen resulted in greater immune reconstitution in patients with immunologic failure despite complete viral suppression with highly active antiretroviral therapy (HAART)... Switching patients to an LPV/r-containing regimen improved CD4(+) counts in patients with prior immunologic failure, and this may be due to an effect of LPV/r on apoptosis.
Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. [2011.02]
OBJECTIVES: To examine whether the overall results of the CASTLE study pertain to both genders, we analysed the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir in 277 female and 606 male patients in the open-label, multinational trial over 96 weeks. The trial is registered with ClinicalTrials.gov, number NCT00272779... CONCLUSIONS: Once-daily atazanavir/ritonavir is an effective and well-tolerated therapeutic option for women and men with HIV-1 infection. The sex-based differences in response may be due to higher discontinuation rates in women.
The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. [2011.02]
S/GSK1349572 is an unboosted, once-daily integrase inhibitor with a novel resistance profile. As standard of care for patients infected with HIV is combination therapy, the potential interaction between S/GSK1349572 and ritonavir-boosted protease inhibitors was evaluated... The most frequent drug-related AEs were diarrhea, dizziness, and headache.
Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial. [2011.01.01]
Given the decline in mortality among HIV-infected patients, it has become increasingly important to consider delayed disease-related and/or anti-HIV therapy-related adverse effects, such as lipodystrophy, when choosing initial therapy. Data from the MONARK trial allowed for comparison of the potential lipodystrophic effects of lopinavir/ritonavir (LPV/r) monotherapy with those of triple therapy with LPV/r plus zidovudine (ZDV) and lamivudine (3TC)...
Clinical Trials Related to Kaletra (Lopinavir / Ritonavir)
A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort [Completed]
The purpose of this study is to compare Kaletra tablets with Kaletra soft-gel capsules to see
if there is any change in the side effects you may have and to see how people in the study
feel about using the tablets.
Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment na├»ve HIV Infected Patients [Completed]
Lopinavir Capsules to Kaletra or Invirase Tablets [Recruiting]
This study will compare the benefit for patients switching from Kaletra« to Invirase«
tablets over remaining on Kaletra« (based on randomization), to elicit the lipid benefits
inferred in previous studies
Kaletra: Therapy With Double Protease Inhibitors [Recruiting]
Therapy with Kaletra and one other protease inhibitor in Human Immunodeficiency
Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients [Terminated]
To demonstrate that patients treated with Kaletra have an improvement in their quality of
life compared to the quality of life they had with their previous NRTI therapy.
Reports of Suspected Kaletra (Lopinavir / Ritonavir) Side Effects
Foetal Exposure During Pregnancy (238),
Maternal Exposure During Pregnancy (134),
Premature Baby (90),
Abortion Spontaneous (60),
Atrial Septal Defect (34), more >>